Fosun International Holds 2025 Annual Results Presentation: Fosun has the Ability to Navigate Through Cycles
HONG KONG, April 1, 2026 /PRNewswire/ -- On 31 March, Fosun International held its 2025 annual results presentation in Shanghai. Guo Guangchang, Chairman of Fosun International; Wang Qunbin, Co-Chairman of Fosun International; Chen Qiyu, Co-CEO of...
Guo Guangchang: Fosun International's NAV reaches HKD18.1 Per Share, Focusing Resources on Core, High‑Growth Areas
HONG KONG, March 31, 2026 /PRNewswire/ -- On the morning of 31 March, Guo Guangchang, Chairman of Fosun International, stated at Fosun International's 2025 annual results presentation that the RMB23.4 billion impairment provision was a "prudent...
Guo Guangchang's Letter to Shareholders: "Repair the Roof While the Sun Is Shining" -- Fosun Aims to Go Further with Greater Stability
HONG KONG, March 30, 2026 /PRNewswire/ -- Guo Guangchang, Chairman of Fosun International Limited (HKEX: 0656), issued a letter to its shareholders today, outlining the Company's strategic direction, accomplishments, and future plans. Dear...
Fosun International: Total Revenue in 2025 Reaches RMB173.43 Billion, with Overseas Revenue Accounting for 54.7%, Aiming to Achieve"RMB10 Billion in Profit"
HONG KONG, March 30, 2026 /PRNewswire/ -- On 30 March, Fosun International (00656.HK) announced its results for the 12 months ended 31 December 2025. In 2025, Fosun's fundamentals remained solid, core industries such as pharmaceuticals and...
Fosun Pharma Announces 2025 Annual Results
Innovation and Globalization Propel Fosun Pharma's High-Quality Growth SHANGHAI, March 24, 2026 /PRNewswire/ -- On 24 March, 2026, Fosun Pharma ("the company", stock code: 600196.SH; 02196.HK), an innovation-driven global pharmaceutical and...
Sanyou Bio's Decade: From an Intelligent Super-Trillion Antibody Library to the "Innovation Hub for Original Drug Discovery"
SHANGHAI, Jan. 31, 2026 /PRNewswire/ -- Amid the surging wave of innovation in China's biopharmaceutical industry, a decade is long enough to witness the full evolution of a sector—from its initial emergence and growth to fundamental transformation....
Insilico Medicine and Hygtia Therapeutics Enter New Global Strategic Collaboration to Co-Develop Novel Brain Penetrant NLRP3 Inhibitor for CNS Diseases treatment
Insilico Medicine and Hygtia Therapeutics, an incubatee of Shenzhen Pengfu Fund of Fosun Health Capital and Fosun Pharma, have entered into an exclusive license and co-development collaboration to advance ISM8969 worldwide. Under the agreement, both...
Sisram Medical Reports Completion of NIFDC Testing for DAXXIFY in China
Marking a Key Milestone Toward Market Launch and Strengthening Sisram's Premium Aesthetics Portfolio HONG KONG, Jan. 5, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred...
Fosun Pharma's Subsidiary Yao Pharma and Pfizer Enter into Exclusive Collaboration and License Agreement
SHANGHAI, Dec. 9, 2025 /PRNewswire/ -- Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, Chongqing Yao Pharmaceutical Company, Limited. ("Yao Pharma"), Shanghai Fosun Pharmaceutical Industrial Development Company...
Fosun Marks Eighth Year at CIIE, Guo Guangchang Calls for More Cutting-Edge Innovation
HONG KONG, Nov. 6, 2025 /PRNewswire/ -- On 5 November 2025, the 8th China International Import Expo (CIIE) opened at the National Exhibition and Convention Center (Shanghai). As a "full-attendance" exhibitor for eight consecutive years, Fosun,...